<?xml version="1.0" encoding="UTF-8"?>
<p>A phase 3 randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of remdesivir in patients hospitalized with mild-to-moderate COVID-19 respiratory disease.[
 <xref rid="ref23" ref-type="bibr">23</xref>] Remdesivir is given as 200 mg of loading dose IV on day 1, followed by 100 mg IV once daily as a maintenance dose for 9 days. The trial is expected to complete by the end of April 2020.
</p>
